In 25 long-term care residents with severe dementia (19 completed both periods), THC/CBD oil did not reduce agitation (CMAI) versus placebo in a crossover trial. As-needed psychotropic use was lower on THC/CBD, a secondary outcome; no related serious adverse events.
RCTn = 25
Bianchi et al. A randomised, double-blind, placebo-controlled crossover trial on cannabinoid-based medication for behavioural disorders in old patients with severe dementia: the study results